[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100247310":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":12,"locations":12,"responsibleParty":25,"collaborators":12,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":12,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":12,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":12,"overallStatus":46,"whyStopped":12,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":12},{"fullName":5,"class":6},"The First People's Hospital of Changzhou","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"regular chemotherapy","NO_INTERVENTION","Patients after chemotherapy are just followed up.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"CIK regimen","EXPERIMENTAL","Patients after chemotherapy will receive at least 3 cycles of Cytokine-induced killer cells (CIK) treatment every 3 months.",[18],"Biological: Cytokine-induced killer cells (CIK)",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"BIOLOGICAL","Cytokine-induced killer cells (CIK)","Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.",[14],{"type":26,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100247310","phase-2-treatment-of-cik-for-patients-with-refractory-non-hodgkin-lymphoma-100247310",false,"NCT02497898","Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma","A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy\n\nExclusion Criteria:\n\n* patients refuse the therapy or have no tolerance for the therapy","ALL","18 Years","80 Years",{"count":38,"type":39},1000,"ESTIMATED","INTERVENTIONAL",[42],"PHASE2","The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and\u002For chemoresistant lymphomas.",[45],"Lymphoma, Non-Hodgkin","NOT_YET_RECRUITING","2015-07-12",{"date":49,"type":39},"2015-07-15",{"date":51,"type":12},"2015-07",{"date":53,"type":39},"2040-07",{"name":5,"class":6}]